Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of ZX1305 recombinant human nerve growth factor eye drops for neurotrophic keratitis
CTR20251509Phase 2Completed
- Sponsor
- Jiangsu Zhongxin Pharmaceutical
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cenegermin in neurotrophic keratitis (NK), sponsored by Jiangsu Zhongxin Pharmaceutical. Started Jun 2025; status: completed.
02
Drugs
cenegermin
03
Conditions
neurotrophic keratitis (NK)
Beyond the preview
Go deeper on CTR20251509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251509.